TW201900199A - Use of Phyllanthus emblica extract for the preparation of a pharmaceutical composition for increasing the activity of mitochondria in the liver - Google Patents

Abstract

An use of an extraction of emblica officinalis in preparing pharmaceutical composition for repairing liver damage, wherein the pharmaceutical composition including the extraction of emblica officinalis improves the ability of performing the oxidative phosphorylation for the synthesis of the adenosine triphosphate (ATP) by mitochondria in the liver cells which are in contact with the free radicals. The pharmaceutical composition including the extraction of emblica officinalis also reduces the proton leakage of the mitochondria, improves the maximal respiration of the mitochondria, improves the coupling efficiency of the adenosine triphosphate in the mitochondria, improves the spare respiratory capacity of the mitochondria, and reduces the amount of the free radical generated in the liver cells.

Description

Use of Glycyrrhizae extract for preparing medical composition for repairing liver damage

The invention relates to the preparation of a medicinal composition for repairing liver damage, in particular to the use of an extract of licorice to prepare a medicinal composition for repairing liver damage.

The liver is one of the main metabolic organs in the human body. The liver's work involves metabolizing sugars, proteins, and lipids, as well as breaking down, converting, and eliminating toxins from the body. However, during the work of the liver, especially when decomposing, converting and eliminating toxins in the body, free radicals are also produced as by-products. Furthermore, for livers damaged by diseases, when the functions of the liver are affected by the diseases, the amount of free radicals generated by the liver while working also increases.

For liver cells, because of the strong oxidizing power of free radicals, the chance of oxidative damage to liver cells and organelles in liver cells exposed to free radicals is greatly increased. In particular, Mitochondria acts as an organelle for oxidative phosphorylation and synthesis of adenosine triphosphate (ATP) in liver cells. When mitochondria are damaged due to oxidative damage caused by a large number of free radicals, hepatocytes cannot self-lower. The mitochondria get a sufficient energy supply. In this way, the low-activity mitochondria will have a serious negative impact on the working conditions of liver cells, and then have a negative impact on the function of the liver.

The present invention provides the use of the extract of Glycyrrhiza indica to prepare a pharmaceutical composition for repairing liver damage, thereby improving the activity of mitochondria in liver cells of the liver, thereby maintaining the normal function of liver cells and repairing liver damage.

The present invention discloses the use of ganko extract to prepare a pharmaceutical composition for repairing liver damage, wherein the ganko extract contains a ganko extract to enhance the oxidative phosphorylation reaction of mitochondria in liver cells exposed to free radicals and The ability to synthesize triphosphate (ATP).

According to the above-mentioned invention disclosed, the use of Euganzi extract for preparing a medicinal composition for repairing liver damage. The medicinal composition comprising Euganzi extract promotes oxidative phosphorylation of mitochondria in liver cells that are in contact with free radicals. Reacts with the ability to synthesize ATP. In this way, the mitochondrial activity in liver cells is maintained, and the mitochondria in liver cells can produce a sufficient amount of triphosphate glycosides for use by liver cells, thereby maintaining normal metabolic work of liver cells. Furthermore, because the efficiency of synthesizing triphosphates required for repairing cell damage is improved, the damaged liver cells have sufficient energy required for repair, thereby accelerating the repair of the liver to a normal state.

The above description of the contents of this disclosure and the description of the following embodiments are used to demonstrate and explain the spirit and principle of the present invention, and provide a further explanation of the scope of the patent application of the present invention.

The detailed features and advantages of the present invention are described in detail in the following embodiments. The content is sufficient for any person skilled in the art to understand and implement the technical content of the present invention, and according to the content disclosed in this specification, the scope of patent applications and the drawings. Anyone skilled in the relevant art can easily understand the related objects and advantages of the present invention. The following examples further illustrate the viewpoints of the present invention in detail, but do not limit the scope of the present invention in any way.

Yu Ganzi (such as Phyllanthus Emblica or Emblica Officinale), also known as Yu grapefruit, nectarine, Amalaka, Pokok Melaka, Indian Gooseberry, belongs to the genus Emblica (Emblica) ), Deciduous sub-arbor, distributed from India to Malaysia and southern China, India is generally considered as the origin.

The method for obtaining the extract of licorice used in the present invention is, for example, carbon dioxide as a supercritical fluid for extracting licorice fruit, or methanol, ethanol, acetone, ethyl acetate, 0.1 to 5% by weight sodium chloride aqueous solution, A potassium chloride aqueous solution, a calcium chloride aqueous solution, a magnesium chloride aqueous solution, or a sodium chloride ethanol solution, a potassium chloride ethanol solution, a calcium chloride ethanol solution, and a magnesium chloride ethanol solution with a concentration of 0.1 to 5% by weight are used as a solvent to extract the fruit of the berry A primary extract was obtained. Next, the primary extract is filtered and purified to obtain the licorice extract used in the present invention. The ganko extract can be spray-dried or vacuum-dried to obtain a ganko extract powder which is easy to preserve.

Emblica extract contains 35% to 55% by weight of Emblicanin-A and Emblicanin-B mixture, 4% to 15% by weight of Punigluconin, 10% to 20% by weight of Pedunculagin, and 5% to 15% by weight Rutin and Gallo-ellagitannoids from 10% to 30% by weight. Amla extract the infrared absorption spectrum to 3403.6 ± 5 cm ^{-1 (cm -1), 2931.6 ±} 5 cm ^{-1 (cm -1), 1385.0 ±} 5 cm ^{-1 (cm -1), 1318.6 ±} 5 cm ^{- 1} (cm ^-1 ), 1623.5 ± 5 cm ^-1 (cm ^-1 ), 1451.3 ± 5 cm ^-1 (cm ^-1 ), 1352.1 ± 5 cm ^-1 (cm ^-1 ), 1218.4 ± 5 cm ^-1 ( cm ^-1 ), 1148.6 ± 5 cm ^-1 (cm ^-1 ), 1035.7 ± 5 cm ^-1 (cm ^-1 ), 3403.6 ± 5 cm ^-1 (cm ^-1 ) have characteristic absorption peaks. The high performance liquid chromatography chromatogram (HPLC Chromatogram) of Euganzi extract has characteristic peak signals at 1.620 ± 0.5 minutes, 2.148 ± 0.5 minutes, 3.265 ± 0.5 minutes and 4.370 ± 0.5 minutes.

The structure of Emblicanin-A (2,3-di-O-galloyl-4,6- (S) -hexahydroxydiphenoyl-2-keto-glucono-lactone) is shown in Formula 1. Formula one

The structure of Emblicanin-B (2,3,4,6-bis- (S) -hexahydroxydiphenoyl-2-keto-glucono-lactone) is shown in Formula 2. Formula two

The structure of Punigluconin (2,3-di-O-galloyl-4,6- (S) -hexahydroxydiphenoyl gluconic acid) is shown in Formula 3. Formula three

The structure of Pedunculagin (2,3,4,6-bis- (S) -hexahydroxydiphenoyl-D-glucose) is shown in Formula 4. Formula four

The structure of Rutin (3 ', 4', 5,7-tetrahydroxyflavono-1,3-O-rhamnoglucoside) is shown in Formula 5. Formula five

When an aqueous solution of licorice extract is provided at a concentration of 100 to 500 micrograms (μg / ml) per milliliter to hepatocytes in contact with free radicals, the licorice extract entering the hepatocytes increases the activity of mitochondria in the hepatocytes. In this way, the amount of triphosphates synthesized by oxidative phosphorylation of the mitochondria activated by the extract of Glycyrrhiza chinensis is increased, the maximum oxygen consumption energy is increased, the pre-stored oxygen consumption capacity is increased, the triphosphate glycoside mediation efficiency is improved, and hydrogen Ion leakage is reduced.

Furthermore, when an aqueous solution of licorice extract is provided at a concentration of 100 to 500 micrograms (μg / ml) per milliliter to liver cells in contact with free radicals, the mitochondria activated by licorice extract is synthesized by oxidative phosphorylation. There was no significant decrease in the amount of triphosphates, no significant decrease in the efficiency of triphosphates, and no significant increase in hydrogen ion leakage. The maximum oxygen consumption energy of the spleenoids activated by the extract of Glycyrrhiza chinensis slightly increased, and the pre-existing oxygen consumption capacity of the mitochondria slightly increased. Therefore, Euganzi extract can be used as an active ingredient in a pharmaceutical composition for repairing liver damage, and Euganzi extract can maintain the activity of mitochondria in liver cells that are in contact with free radicals in liver cells that are close to those that are not in contact with free radicals. Mitochondrial activity. Furthermore, because the efficiency and ability of synthesizing triphosphates required for repairing cell damage is improved, the damaged liver cells have sufficient energy required for repair, thereby accelerating the repair of the liver to a normal state.

A method for providing a Gan Gan extract or a pharmaceutical composition containing Gan Gan extract to liver cells is, for example, ingesting a Gan Gan extract or a pharmaceutical composition containing Gan Gan extract by mouth. The effective dose of Glycyrrhizae extract when provided to the cells in an edible manner is 1.081 grams (g) to 5.405 grams (g). The conversion formula is as follows: effective dose in human body (mg) = effective dose in cell experiment (μg / ml) × mouse weight (g) × conversion factor × human weight (kg). The conversion factor is obtained by looking up the conversion factor table for the dose per kilogram of body weight of animals and humans. When the weight of the mouse is 20 g and the weight of the human body is 60 kg, the conversion factor is 9.01.

In order to facilitate the ingestion of the extract of licorice in the form of food, the extract of licorice can be made into, for example, a liquid, solid, granular, powdery, pasty, or gelled processed licorice extract. The processed extracts of cumin seeds can be used as excipients or flavoring agents as additives to enhance the flavor and ease of consumption.

Excipients are, for example, starches such as wheat starch, rice starch, corn starch, potato starch, dextrin, and cyclodextrin; crystalline celluloses; lactose, glucose, granulated sugar, reduced maltose, caramel, fructooligosaccharides, and emulsified oligosaccharides And other sugars; sorbitol, erythritol, xylitol, lactitol, mannitol and other sugar alcohols.

Flavoring agents are, for example, various fruit extracts such as longan extract, lychee extract, grapefruit extract; various fruit juices such as apple juice, orange juice, and lemon juice; various spices such as peach flavor, plum flavor, and yogurt flavor; acesulfame Various sweeteners such as potassium acid, sucralose, erythritol, oligosaccharides, mannose, xylitol, isomerized sugars; various acidifiers such as citric acid, malic acid, tartaric acid, gluconic acid; green tea, oolong tea, Various tea ingredients such as Banaba Tea, Eucommia Tea, Tieguanyin Tea, 薏苡 Tea, Aescinate Tea, White Tea, Kumbu Tea; Coffee Arabica, Coffee Robusta, Various coffee ingredients such as Coffee Liberica.

Furthermore, the gangan extract or a pharmaceutical composition containing the gangan extract can also be coated in a capsule to facilitate ingestion of the gangan extract through the mouth. The gangan extract or the pharmaceutical composition containing the gangan extract may be coated in a hard capsule in the form of a dry powder. Coconut oil extract or pharmaceutical composition containing coconut oil extract can also be coated in soft capsules in the form of solution, suspension, paste, powder or granule.

The fats and oils used to dissolve or disperse the licorice extract in soft capsules are e.g. pear oil, almond oil, linseed oil, cumin oil, white perilla oil, olive oil, olive squalene, sweet orange oil, chestnut Orange roughy oil, sesame oil, garlic oil, cocoa butter, pumpkin seed oil, chamomile oil, carrot oil, courgette oil, tallow fatty acids, Hawaiian stone oil, bilberry oil, brown rice germ oil, rice oil, wheat germ Oil, safflower oil, shea oil, liquid shea oil, perilla oil, soybean oil, evening primrose oil, camellia oil, corn oil, rapeseed oil, saw palmetto extract oil, emu oil, Peach kernel oil, parsley oil, castor oil, sunflower oil, grape seed oil, borage oil, Australian walnut oil, meadowfoam oil, cottonseed oil, peanut oil, turtle oil, mink oil, egg butter, Fish oil, palm oil, palm kernel oil, wood wax, coconut oil, long chain / medium chain / short chain fatty acid triglycerides, diglycerides, tallow, lard, squalene, squalane, tincture Alkanes, and hydrides of these oils and fats. Among them, borage oil and evening primrose oil contain a large amount of Gamma-Linolenic Acid (GLA). Gamma-linolenic acid is an essential fatty acid of the human body, which has moisturizing, promotes cell regeneration, and promotes brown fat activity. Degree to promote fat burning function.

In addition, colorants, preservatives, tackifiers, binding agents, disintegrating agents, dispersants, stabilizers, gelling agents, antioxidants, surfactants, preservatives, pH adjusters, etc. are added in accordance with government regulations. It can also be added to the processed extract of Yuganzi according to the dosage standard stipulated by the government unit and the requirements of processing production.

The following uses Example 1 to Example 3 of the present invention, control examples, and comparative examples to explain the use of the extract of Glycyrrhiza indica in the present invention for preparing a pharmaceutical composition for repairing liver damage, and experimental tests are performed to illustrate the disclosed properties of the present invention. The efficacy of Glycyrrhiza indica extract for preparing a pharmaceutical composition for repairing liver damage.

The fruit extract of Emblica Officinalis used in the experiment of the present invention is immersed in a 1% by weight sodium chloride aqueous solution, and heated in a steam bath at 65 ° C to 75 ° C for one Hours, followed by filtration, followed by freezing for another 3 days, followed by a spray dry procedure to obtain the powder of the guacamole extract. After drying, the type of the extract of licorice was brown powder. Emblican extract contains 27% by weight of Emblicanin-A, 23% by weight of Emblicanin-B, 8% by weight of Punigluconin, 14% by weight of Pedunculagin, 10% by weight of Rutin and 10% to 30% by weight % Of Gallo-ellagitannoids. The licorice extract of the present invention is not limited to the extract of Emblica Officinalis , and other licorice extracts with different scientific names but similar components also have the same effect.

FIG. 1 is an infrared absorption spectrum of the licorice extract used in Examples 1 to 3 of the present invention. FIG. 2 is a high performance liquid chromatography spectrum used in Examples 1 to 3 of the present invention. As shown in Figure 1, the infrared absorption spectrum of the extract of P. chinensis was at 3403.6 cm ^-1 (cm ^-1 ), 2931.6 cm ^-1 (cm ^-1 ), 1385.0 cm ^-1 (cm ^-1 ), 1318.6 cm ^-1 ( cm ^-1 ), 1623.5 cm ^-1 (cm ^-1 ), 1451.3 cm ^-1 (cm ^-1 ), 1352.1 cm ^-1 (cm ^-1 ), 1218.4 cm ^-1 (cm ^-1 ), 1148.6 cm ^-1 ( cm ^-1 ), 1035.7 cm ^-1 (cm ^-1 ), 3403.6 cm ^-1 (cm ^-1 ) have characteristic absorption peaks. As shown in FIG. 2, the HPLC chromatograms of the extract of Glycyrrhiza indica have characteristic peak signals at 1.620 minutes, 2.148 minutes, 3.265 minutes, and 4.370 minutes.

The cells used in the experiment were Hep-G2 cells. Experimental samples were prepared by implanting 20,000 hepatocytes into each well of a 24-well plate and culturing for 24 hours. Next, the culture fluid in the well was removed, and the hepatocytes in the well were processed according to the conditions of the examples, control examples, and comparative examples.

In the course of the experiment, when preparing the experimental samples of Examples 1 to 3, firstly, an aqueous solution of Coconut Extract was added to the well where the liver cells were located and soaked for 24 hours. Next, the aqueous solution in the well where the liver cells are located is removed, and a 1.5 mM H ₂ O ₂ aqueous solution is added to the well, and the cells are immersed in the 1.5 mM H ₂ O ₂ aqueous solution for 60 minutes. Next, the H ₂ O ₂ aqueous solution in the well where the liver cells are located is removed, and the liver cells are washed with phosphate buffered saline (PBS) to complete the preparation of the experimental samples of Examples 1 to 3.

When preparing the experimental sample of the control example, after removing the culture fluid in the well where the hepatocytes are located, the remaining hepatocytes are the experimental sample of the control example. To prepare the experimental sample of the comparative example, firstly add an aqueous solution of H ₂ O ₂ at a concentration of 1.5 mM to the wells, and immerse the hepatocytes in an aqueous solution of H ₂ O ₂ at a concentration of 1.5 mM for 60 minutes. Next, the H ₂ O ₂ aqueous solution in the well where the liver cells are located, and the cells were washed with Phosphate buffered saline (PBS), and the experimental sample preparation of the comparative example was completed.

In the first embodiment, the concentration of the aqueous solution of the licorice extract is 200 micrograms (μg / ml) per milliliter. In the second embodiment, the concentration of the aqueous solution of the licorice extract was 250 micrograms (μg / ml) per milliliter. In Example 3, the concentration of the aqueous solution of the licorice extract was 500 micrograms (μg / ml) per milliliter.

Next, the hippocampal bioenergy measuring instrument was used to measure the oxygen consumption of the hepatocytes in the first to third embodiments, the control example and the comparative example. According to the literature, treating cells with hydrogen peroxide can simulate the intracellular oxidation to generate free radicals, thereby studying the mitochondrial activity of cells under oxidative stress. Therefore, after the liver cell lines of Examples 1 to 3 and the comparative example were treated with hydrogen peroxide, the oxygen consumption of liver cells was measured with a hippocampal bioenergy meter, and it was used to understand the effects of the extract of Ganganzi on liver cells. Effects of Mitochondrial Activity.

The measurement principle and process of the hippocampal bioenergy meter are as follows. First, the basal oxygen consumption of the cells in the well is detected. Next, an inhibitor of triphosphate synthase is added to inhibit the production of triphosphate by the mitochondria. At this time, the reduced oxygen consumption is the oxidative phosphorylation reaction of the mitochondria to synthesize the oxygen consumption of triphosphate. This is the basic oxygen consumption (Basal Respiration) of the mitochondria. An inhibitor of triphosphate glycoside synthase is, for example, Oligomycin. Then, an appropriate anti-coupling agent is added, and in the case that the electron transport chain of the inner membrane of the mitochondria is damaged, the mitochondria are allowed to idle under the limit state to evaluate the maximal oxygen respiration of the mitochondria. The anti-coupling agent is, for example, Carbonyl cyanide-4- (trifluoromethoxy) phenylhydrazone (FCCP). Finally, the addition of an electron transfer chain inhibitor has completely turned off the mitochondrial oxygen consumption, thereby confirming the measured background value, which is the non-mitochondrial oxygen consumption (Non-mitochondrial Respiration). The electron transport chain inhibitor is, for example, a combination of Rotenone and Antimycin A.

The basal oxygen consumption of the mitochondria is equal to the basal oxygen consumption of the cells minus the non-mitochondrial oxygen consumption. The basic oxygen consumption of the mitochondria minus the amount of oxygen consumed by the synthesis of linear glucosides of triphosphate is equal to the oxygen consumption to overcome the hydrogen ion leakage (Proton Leakage). The maximum oxygen consumption of the mitochondria minus the basic oxygen consumption of the mitochondria is equal to the Spare Respiratory Capacity of the mitochondria. The mitochondrial triphosphate glycoside mediation efficiency (Coupling Efficiency) is equal to the oxygen consumption of the synthetic triphosphate glycoside divided by the mitochondrial base oxygen consumption.

The experimental parameters and experimental measurement results of the first embodiment to the eighth embodiment, the comparative example 1 to the comparative example 2 and the control example are shown in Table 1 and FIGS. 3 to 7. The experimental measurement results of the oxygen picomolar consumption per minute of microgram protein (pmol / min / μg protein) presented in Table 1 are the experimental measurement results after the cell mass has been standardized. FIG. 3 is a schematic diagram of oxygen consumption of synthetic triphosphates in Examples 1 to 3, Comparative Examples and Control Examples of the present invention. FIG. 4 is a schematic diagram of oxygen consumption for overcoming hydrogen ion leakage in Examples 1 to 3, Comparative Examples and Control Examples of the present invention. FIG. 5 is a schematic diagram of the oxygen consumption of the maximum oxygen consumption capacity of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 6 is a schematic diagram of the matching efficiency of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 7 is a schematic diagram of the pre-stored oxygen consumption capacity of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 8 is a schematic diagram of oleic acid-induced free radical generation in liver cells in the second, third, comparative and control examples of the present invention.

Table I

As shown in FIG. 3, the oxygen consumption of the synthetic triphosphates in Examples 1 to 3 is higher than the oxygen consumption of the synthetic triphosphates in Comparative Examples. As shown in FIG. 5, the maximum oxygen consumption energy of the mitochondria of Examples 1 to 3 is higher than the maximum oxygen consumption energy of the mitochondria of Comparative Examples. As shown in FIG. 6, the matching efficiency of the squid body of Examples 1 to 3 is higher than the matching efficiency of the squid body of the comparative example. As shown in FIG. 7, the pre-stored oxygen consumption capacity of the mitochondria of Examples 1 to 3 is higher than the pre-stored oxygen consumption capacity of the mitochondria of Comparative Example 1. Therefore, it can be seen from FIG. 3, FIG. 5 to FIG. 7 that after the liver cells of Example 1 to Example 3 are treated with the extract of Ganzizi, the activity of mitochondria in the liver cells is improved. Furthermore, the increased pre-stored oxygen consumption capacity of mitochondria also represents an improvement in the ability of mitochondria and hepatocytes to respond to various conditions that can cause pressure on the cells.

As shown in FIG. 4, the leakage amount of hydrogen ions of the mitochondria of Examples 1 to 3 is lower than that of the mitochondria of the Comparative Example. Therefore, it can be seen from FIG. 4 that after the liver cells of the first to third embodiments are treated with the extract of ganzi, the ability of the mitochondria in the hepatocytes to resist the oxidative damage of free radicals is improved.

In addition, as shown in FIG. 3 to FIG. 7, compared with the mitochondria in the hepatocytes of the control example, the mitochondria in the hepatocytes of the first to third embodiments were activated by the extracts of glucosamine. The number of triphosphates synthesized by oxidative phosphorylation did not decrease significantly, the efficiency of triphosphates did not decrease significantly, and hydrogen ion leakage did not significantly increase. The maximum oxygen consumption energy of the spleenoids activated by the extract of Glycyrrhiza chinensis slightly increased, and the pre-existing oxygen consumption capacity of the mitochondria slightly increased. Therefore, Yuganzi extract can maintain the activity of mitochondria in liver cells exposed to free radicals, which is close to the activity of mitochondria in liver cells not exposed to free radicals.

Furthermore, as shown in FIG. 3, the oxygen consumption of the synthetic triphosphates in Examples 1 to 3 is close to the control example, and is significantly higher than that of the comparative example. As shown in FIG. 4, the oxygen consumption for overcoming hydrogen ion leakage in Examples 1 to 3 is slightly higher than that in the control example, but significantly lower than that in the comparative example. Therefore, it can be seen from FIG. 3 and FIG. 4 that the leakage amount of hydrogen ions in the inner membrane of the mitochondrial body of Examples 1 to 3 does not increase significantly as compared with the leakage amount of hydrogen ions in the inner membrane of the mitochondrial body of the comparative example, which represents the inside of the mitochondria. There was no severe damage on the membrane that caused a large leakage of hydrogen ions. Therefore, the amount of oxygen consumed by the mitochondria to retransmit hydrogen ions to the membrane space is reduced, so that the oxygen consumption for synthesizing triphosphates and the efficiency of the triphosphate glycosides are close to the control example.

As shown in FIG. 8, based on the amount of free radical generation in the hepatocytes of the control example, the rate of free radical generation in the hepatocytes of Examples 2 and 3 is lower than that of the hepatocytes of the comparative example. It shows that the amount of free radicals generated in the liver cells of Examples 2 and 3 is lower than the amount of free radicals generated in the liver cells of Comparative Example 1. Therefore, it can be seen from FIG. 8 that the higher the concentration of the extract of Glycyrrhizae provided to the liver cells, the better the effect of inhibiting the generation of free radicals in the liver cells. Hepatocytes treated with an aqueous solution of Euganzi extract at a concentration of 100 micrograms to 500 micrograms (μg / ml) per milliliter are protected by Euganzi extract, which reduces free radicals in hepatocytes to the mitochondria in hepatocytes. Destruction of the membrane. Therefore, the aqueous solution of the extract of Glycyrrhiza chinensis at a concentration of 100 micrograms to 500 micrograms (μg / ml) per milliliter has the effect of protecting mitochondria in liver cells. In this way, the time for mitochondria to disintegrate can be delayed, thereby delaying the occurrence of hepatocyte apoptosis.

According to the above-mentioned invention disclosed, the use of Euganzi extract for preparing a medicinal composition for repairing liver damage. The medicinal composition comprising Euganzi extract promotes oxidative phosphorylation of mitochondria in liver cells that are in contact with free radicals. Reacts with the ability to synthesize ATP. In this way, the mitochondrial activity in liver cells is maintained, and the mitochondria in liver cells can produce a sufficient amount of triphosphate glycosides for use by liver cells, thereby maintaining normal metabolic work of liver cells. As the efficiency and ability of synthesizing triphosphates required for repairing cell damage is improved, the damaged liver cells have sufficient energy required for repair, thereby accelerating the repair of the liver to a normal state.

Furthermore, the provision of the extract of Ganzizi to hepatocytes reduces the damage of free radicals in hepatocytes to the mitochondrial and inner membrane of hepatocytes. Therefore, Yuganzi extract aqueous solution also has the effect of protecting mitochondria in liver cells. In this way, the time for mitochondria to disintegrate can be delayed, thereby delaying the occurrence of hepatocyte apoptosis.

Although the present invention is disclosed in the foregoing embodiments, it is not intended to limit the present invention. The numerical values or numerical ranges shown in the present invention include tolerance ranges that can be understood by a person having ordinary knowledge in the field to which the present invention belongs. Changes and modifications made without departing from the spirit and scope of the present invention belong to the patent protection scope of the present invention. For the protection scope defined by the present invention, please refer to the attached patent application scope.

no

FIG. 1 is an infrared absorption spectrum of the licorice extract used in Examples 1 to 3 of the present invention. FIG. 2 is a high-performance liquid chromatogram of the extract of licorice used in Examples 1 to 3 of the present invention. FIG. 3 is a schematic diagram of oxygen consumption of synthetic triphosphates in Examples 1 to 3, Comparative Examples and Control Examples of the present invention. FIG. 4 is a schematic diagram of oxygen consumption for overcoming hydrogen ion leakage in Examples 1 to 3, Comparative Examples and Control Examples of the present invention. FIG. 5 is a schematic diagram of the oxygen consumption of the maximum oxygen consumption capacity of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 6 is a schematic diagram of the matching efficiency of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 7 is a schematic diagram of the pre-stored oxygen consumption capacity of the first to third embodiments of the present invention, the comparative example and the control example. FIG. 8 is a schematic diagram of oleic acid-induced hepatocyte free radical generation in the second, third, comparative and control examples of the present invention.

Claims (13)

A use of licorice extract for preparing a medicinal composition for repairing liver damage, wherein the pharmaceutical composition containing the licorice extract enhances a plurality of hepatocytes in contact with free radicals, and a plurality of mitochondria are subjected to a The ability of oxidative phosphorylation to synthesize ATP. The use of Yuganzi extract as described in claim 1 for preparing a pharmaceutical composition for repairing liver damage, wherein the infrared absorption spectrum of the Yuganzi extract is at 3403.6 ± 5 cm ^-1 (cm ^-1 ), 2931.6 ± 5 cm ^{-1 (cm -1), 1385.0 ±} 5 cm ^{-1 (cm -1), 1318.6 ±} 5 cm ^{-1 (cm -1), 1623.5 ±} 5 cm ^{-1 (cm -1), 1451.3 ±} 5 cm ^{- 1} (cm ^-1 ), 1352.1 ± 5 cm ^-1 (cm ^-1 ), 1218.4 ± 5 cm ^-1 (cm ^-1 ), 1148.6 ± 5 cm ^-1 (cm ^-1 ), 1035.7 ± 5 cm ^-1 ( cm ^-1 ), 3403.6 ± 5 cm ^-1 (cm ^-1 ) have characteristic absorption peaks. The use of Yuganzi extract as described in claim 1 for preparing a pharmaceutical composition for repairing liver damage, wherein the high-performance liquid chromatography chromatogram (HPLC Chromatogram) of the Yuganzi extract is 1.620 ± 0.5 minutes, 2.148 ± 0.5 minutes, 3.265 ± 0.5 minutes and 4.370 ± 0.5 minutes have characteristic peak signals. The use of Yuganzi extract as described in claim 1 for preparing a pharmaceutical composition for repairing liver damage, wherein the Yuganzi extract is obtained by extracting Yuganzi fruit with saline solution. The use of Yuganzi extract according to claim 1 for preparing a pharmaceutical composition for repairing liver damage, wherein the Yuganzi extract contains 35% to 55% by weight of a mixture of Emblicanin-A and Emblicanin-B, and a weight percentage 4% to 15% of Punigluconin, 10% to 20% by weight of Pedunculagin, 5% to 15% of Rutin and 10% to 30% of Gallo-ellagitannoids. The use of Yuganzi extract as described in claim 1 for the preparation of a pharmaceutical composition for repairing liver damage, wherein the step of providing the pharmaceutical composition comprising the Ganzi extract to the liver cells comprises eating the pharmaceutical composition. . The use of Yuganzi extract as described in claim 1 for preparing a pharmaceutical composition for repairing liver damage, wherein the effective dose of the Yuganzi extract is from 1.081 grams (g) to 5.405 grams (g). The use of the extract of Glycyrrhiza indica as described in claim 7 for preparing a pharmaceutical composition for improving mitochondrial activity in the liver, wherein the pharmaceutical composition is coated in a soft capsule or a hard capsule. The use of Yuganzi extract according to any one of claim 1 to claim 8 for preparing a pharmaceutical composition for repairing liver damage, wherein the medicinal composition containing the Ganganzi extract reduces the mitochondria Proton Leakage. The use of Yuganzi extract according to any one of claim 1 to claim 8 for preparing a pharmaceutical composition for repairing liver damage, wherein the medicinal composition containing the Yuganzi extract enhances the mitochondria Maximal respiration. The use of Yuganzi extract according to any one of claim 1 to claim 8 for preparing a pharmaceutical composition for repairing liver damage, wherein the medicinal composition containing the Yuganzi extract enhances the mitochondria Coupling efficiency The use of Yuganzi extract according to any one of claim 1 to claim 8 for preparing a pharmaceutical composition for repairing liver damage, wherein the medicinal composition containing the Yuganzi extract enhances the mitochondria Spare respiratory capacity The use of Yuganzi extract according to any one of claim 1 to claim 8 for the preparation of a pharmaceutical composition for repairing liver damage, wherein the pharmaceutical composition comprising the Ganganzi extract reduces the intracellular content of the liver cells Free radical generation.